載入中
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
前收盤價
US$1.31
−US$0.0301 · -2.25%
盤後
US$1.31
US$0.00 · 0.00%
10月12日 下午4:04 ET
盤中時間採用ET。市場資料可能有所延遲。
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
日內區間
目前US$1.31
52週區間
目前US$1.31
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
44
合理估值
情緒
60
多空交錯
風險
66
高風險
動能
31
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
日內區間
目前US$1.31
52週區間
目前US$1.31
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 362.98萬 USD | 141.49萬 USD | 645.51萬 USD | 744.59萬 USD | 520.13萬 USD |
| 銷售、一般及管理費用 | 513.71萬 USD | 308.19萬 USD | 348.25萬 USD | 742.46萬 USD | 711.82萬 USD |
| 營業費用 | 876.68萬 USD | 449.68萬 USD | 993.76萬 USD | 1487.05萬 USD | 1231.95萬 USD |
| 利息收入 | 1078 USD | — | — | — | — |
| 利息支出 | −6619 USD | 1.8萬 USD | 1.01萬 USD | 7701 USD | 4.65萬 USD |
| 折舊和攤銷 | 11.07萬 USD | 5.07萬 USD | 5.07萬 USD | 2.31萬 USD | 3549 USD |
| 營業利益 | −876.68萬 USD | −449.68萬 USD | −993.76萬 USD | −1487.05萬 USD | −1231.95萬 USD |
| 淨利 | −877.24萬 USD | −451.49萬 USD | −994.77萬 USD | −1487.82萬 USD | −1236.21萬 USD |
公司資料更新於 2026年10月13日。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
